Tempest Therapeutics Stock (NASDAQ:TPST)
Previous Close
$10.51
52W Range
$5.36 - $20.67
50D Avg
$8.44
200D Avg
$9.26
Market Cap
$47.55M
Avg Vol (3M)
$86.80K
Beta
-2.29
Div Yield
-
TPST Company Profile
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.